Skip to content
Buy This GLP
← Research
Evidence

Liraglutide in Adolescents With Obesity: A 26-Week Taiwan Study

A Taiwan study reported an average 4.4 kg weight loss at 26 weeks among adolescents receiving liraglutide. The study had no comparison group.

Editorial profile: Wesley JenkinsBuy This GLP Editorial Team4 min read
Weight change, mean and one standard deviationno changeweek 13-2.7 ± 3.8 kgweek 26-4.4 ± 5.7 kgThe bands show variation, not individual results.

The study enrolled 41 adolescents with obesity receiving liraglutide in Taiwan [1]. Other research on how long teens stay on GLP-1 drugs looks at treatment beyond the first prescription. This study measured changes at weeks 13 and 26.

How much did weight change?

Average weight fell 2.7 kg by week 13 and 4.4 kg by week 26 [1]. The corresponding standard deviations were 3.8 kg and 5.7 kg. These figures show variation. They do not tell us how many participants gained weight. Nineteen participants had a history of liver impairment.

The study had no untreated comparison group. Differences in when GLP-1 effects show up can matter when comparing milestones across studies. This study cannot separate the effect of liraglutide from growth, clinic support or other changes.

How the study dose compares with the US label

Mean daily dose in this study was 1.4 mg [1]. That describes what this group received in practice. The US Saxenda label covers eligible patients aged 12 or older with obesity and weight over 60 kg [2]. Its recommended pediatric maintenance dose is 3 mg daily, with 2.4 mg as an option if 3 mg is not tolerated. The study cannot tell families which dose to choose.

What the study found on side effects

Eight of 41 participants reported adverse events, all mild [1]. Stomach or intestinal symptoms were most frequent. Nobody stopped treatment because of intolerance. A study this small cannot reliably detect uncommon side effects.

Frequently asked

How much weight did adolescents lose in the study?
Average weight fell 2.7 kg by week 13 and 4.4 kg by week 26. The figures describe the study group.
What dose did participants receive?
The mean daily dose was 1.4 mg. Participants did not all take the same dose. The study cannot establish the best dose.
How many participants had side effects?
Eight of 41 reported adverse events, all mild. Nobody discontinued because of intolerance. The study was too small to estimate uncommon risks.

Sources

  1. [1] Chiu CF, et al. (2026). A multicenter real-world study on the safety and effectiveness of the glucagon-like peptide-1 receptor agonist (liraglutide) in adolescents with obesity in Taiwan Obesity Research & Clinical Practice. PMID 42744726
  2. [2] Novo Nordisk Inc. (2026). Saxenda prescribing information, sections 1, 2.2 and 8.4 DailyMed, U.S. National Library of Medicine. Source

Where to get it

Price the injectable sellers

The desk lists every seller that publishes an injectable figure, with the advertised price struck against the one a buyer is billed.

Open the price desk →

More in Evidence